



PRESS RELEASE

Moberg Pharma's report for the first quarter to be published on May 9 - Invitation to teleconference

STOCKHOLM, May 3rd, 2017 - On May 9th 2017, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its interim report for January - March 2017. Investors, analysts and journalists are hereby invited to participate in a teleconference at 03:00 pm (CET) on the same date.

The teleconference will be hosted by Moberg Pharmas's CEO Peter Wolpert and CFO Anna Ljung. The presentation will be held in English.

Date: May 9th 2017
Time: 03:00 pm (CET)

To participate in the conference, please dial in on any number below before the start of the call:

SE: +46 8 566 426 95
US: +1 646 502 51 20

The quarterly report and other information material will be made public on:

<http://www.mobergpharma.com/investors/calendarpresentations>

For additional information, please contact:

Peter Wolpert, CEO, Phone: +46 707 35 71 35, E-mail: peter.wolpert@mobergpharma.se

Anna Ljung, CFO, Phone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal[®], Kerasal Nail[®], Balmex[®], NewSkin[®], Dermoplast[®], Domeboro[®] and Fiber Choice[®]. Kerasal Nail[®] (Emtrix[®] or Nalox[™] in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).